| Date Checked | 2025-12-21 23:26:05 |
|---|---|
| Graham Number | (PB)nan vs (PE)0.00 |
| Over / Under Value Percentage | 0.00% vs 0.00% |
| Dividend Yield | 0.00% |
| Dividend Date | None |
| Symbol | BPMC |
| AssetType | Common Stock |
| Name | Blueprint Medicines Corp |
| Description | Blueprint Medicines Corporation, a precision therapy company, develops drugs for people with cancer and blood disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is headquartered in Cambridge, Massachusetts. |
| CIK | 1597264 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | LIFE SCIENCES |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Address | 45 SIDNEY STREET, CAMBRIDGE, MA, US |
| OfficialSite | https://www.blueprintmedicines.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-03-31 |
| MarketCapitalization | 6576728000 |
| EBITDA | -158367008 |
| PERatio | 0 |
| PEGRatio | 0 |
| BookValue | 5.3 |
| DividendPerShare | None |
| EPS | -2.51 |
| RevenuePerShareTTM | 8.85 |
| ProfitMargin | -0.277 |
| OperatingMarginTTM | -0.275 |
| ReturnOnAssetsTTM | -0.0975 |
| ReturnOnEquityTTM | -0.477 |
| RevenueTTM | 562121000 |
| GrossProfitTTM | 542347000 |
| DilutedEPSTTM | -2.51 |
| QuarterlyEarningsGrowthYOY | -0.994 |
| QuarterlyRevenueGrowthYOY | 0.555 |
| AnalystTargetPrice | 126.1 |
| AnalystRatingStrongBuy | 5 |
| AnalystRatingBuy | 10 |
| AnalystRatingHold | 5 |
| AnalystRatingSell | 1 |
| AnalystRatingStrongSell | 0 |
| TrailingPE | - |
| ForwardPE | - |
| PriceToSalesRatioTTM | 12.02 |
| PriceToBookRatio | 22.62 |
| EVToRevenue | 12.99 |
| EVToEBITDA | 343.71 |
| Beta | 0.83 |
| 52WeekHigh | 121.9 |
| 52WeekLow | 73.04 |
| 50DayMovingAverage | 88.48 |
| 200DayMovingAverage | 93.86 |
| SharesOutstanding | 64582000 |
| ExDividendDate | None |
| dateChecked | 2025-12-21 23:26:05 |
| fresh | 1 |